These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36501086)

  • 41. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
    Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
    Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early improvement of global longitudinal strain after iron deficiency correction in heart failure with reduced ejection fraction.
    Sutil-Vega M; Rizzo M; Colomer-Asenjo Í; Taibi F; Castaldo F; Del Castillo-Vázquez P; Mallofré N; Torres-Ruiz G; Rojas P; Martínez-Rubio A
    Echocardiography; 2024 Jan; 41(1):e15726. PubMed ID: 38078698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous iron supplementation in heart failure patients induces temporary endothelial dysfunction with release of endothelial microvesicles.
    Mause SF; Berger M; Lim HY; Vogt F; Brandenburg V; Stöhr R
    Front Immunol; 2022; 13():1092704. PubMed ID: 36761158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
    Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
    Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
    Nouhravesh N; Garg J; Rockhold FW; De Pasquale CG; O'Meara E; Lewis GD; Butler J; Harrington J; Ezekowitz JA; Ponikowski P; Troughton RW; Wong YW; Blackman N; Numan S; Adamczyk R; Hernandez AF; Mentz RJ
    Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38896006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores.
    Paterek A; Kępska M; Sochanowicz B; Chajduk E; Kołodziejczyk J; Polkowska-Motrenko H; Kruszewski M; Leszek P; Mackiewicz U; Mączewski M
    Sci Rep; 2018 Oct; 8(1):15758. PubMed ID: 30361476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.
    Rangwala BS; Zuhair V; Mustafa MS; Mussarat A; Khan AW; Danish F; Fatima Zaidi SM; Rehman FU; Shafique MA
    Future Sci OA; 2024 Dec; 10(1):2367956. PubMed ID: 38982752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study.
    Fitzsimons S; Poppe KK; Choi Y; Devlin G; Lund M; Lam CSP; Troughton R; Richards AM; Doughty RN
    J Card Fail; 2022 Aug; 28(8):1255-1263. PubMed ID: 35051624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials.
    Rosano GM; Kalantar-Zadeh K; Jankowska EA
    ESC Heart Fail; 2023 Apr; 10(2):1294-1304. PubMed ID: 36722321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
    Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF).
    Yeo TJ; Yeo PS; Hadi FA; Cushway T; Lee KY; Tai BC; Lam CS
    ESC Heart Fail; 2016 Jun; 3(2):71-76. PubMed ID: 27774269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
    Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Bertrand PB; Tang WHW; Mullens W
    Eur J Heart Fail; 2022 Jun; 24(6):1106-1113. PubMed ID: 35303390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.